Y.S.P. Southeast Asia Holding Berhad Past Earnings Performance
Past criteria checks 5/6
Y.S.P. Southeast Asia Holding Berhad has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 8.9% annually. Revenues have been growing at an average rate of 3.9% per year. Y.S.P. Southeast Asia Holding Berhad's return on equity is 9.4%, and it has net margins of 10.5%.
Key information
8.1%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.7% |
| Revenue growth rate | 3.9% |
| Return on equity | 9.4% |
| Net Margin | 10.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Y.S.P. Southeast Asia Holding Berhad's (KLSE:YSPSAH) Dividend Will Be Increased To MYR0.11
Apr 26
Estimating The Intrinsic Value Of Y.S.P. Southeast Asia Holding Berhad (KLSE:YSPSAH)
Mar 03We Think You Can Look Beyond Y.S.P. Southeast Asia Holding Berhad's (KLSE:YSPSAH) Lackluster Earnings
Mar 04Y.S.P. Southeast Asia Holding Berhad (KLSE:YSPSAH) Seems To Use Debt Quite Sensibly
Sep 01Should Y.S.P. Southeast Asia Holding Berhad (KLSE:YSPSAH) Be Part Of Your Dividend Portfolio?
Mar 31Y.S.P. Southeast Asia Holding Berhad's (KLSE:YSPSAH) Shareholders Are Down 15% On Their Shares
Mar 10Is Y.S.P. Southeast Asia Holding Berhad's (KLSE:YSPSAH) Recent Price Movement Underpinned By Its Weak Fundamentals?
Feb 11Is Y.S.P. Southeast Asia Holding Berhad (KLSE:YSPSAH) A Risky Investment?
Jan 21Is Y.S.P. Southeast Asia Holding Berhad (KLSE:YSPSAH) An Attractive Dividend Stock?
Dec 30Y.S.P. Southeast Asia Holding Berhad's(KLSE:YSPSAH) Share Price Is Down 11% Over The Past Three Years.
Dec 09
Revenue & Expenses BreakdownBeta
How Y.S.P. Southeast Asia Holding Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 355 | 37 | 104 | 0 |
| 30 Sep 23 | 348 | 35 | 106 | 0 |
| 30 Jun 23 | 351 | 40 | 105 | 0 |
| 31 Mar 23 | 348 | 39 | 102 | 0 |
| 31 Dec 22 | 334 | 34 | 98 | 0 |
| 30 Sep 22 | 326 | 32 | 95 | 0 |
| 30 Jun 22 | 304 | 26 | 91 | 0 |
| 31 Mar 22 | 292 | 19 | 91 | 0 |
| 31 Dec 21 | 282 | 15 | 92 | 0 |
| 30 Sep 21 | 284 | 16 | 93 | 0 |
| 30 Jun 21 | 285 | 12 | 94 | 0 |
| 31 Mar 21 | 288 | 19 | 94 | 0 |
| 31 Dec 20 | 297 | 22 | 95 | 0 |
| 30 Sep 20 | 298 | 22 | 95 | 0 |
| 30 Jun 20 | 300 | 29 | 97 | 0 |
| 31 Mar 20 | 301 | 24 | 98 | 0 |
| 31 Dec 19 | 296 | 23 | 97 | 0 |
| 30 Sep 19 | 295 | 26 | 98 | 0 |
| 30 Jun 19 | 294 | 24 | 95 | 0 |
| 31 Mar 19 | 292 | 28 | 93 | 0 |
| 31 Dec 18 | 289 | 30 | 91 | 0 |
| 30 Sep 18 | 281 | 29 | 89 | 0 |
| 30 Jun 18 | 274 | 26 | 88 | 0 |
| 31 Mar 18 | 266 | 18 | 86 | 0 |
| 31 Dec 17 | 262 | 20 | 85 | 0 |
| 30 Sep 17 | 253 | 27 | 80 | 0 |
| 30 Jun 17 | 246 | 28 | 79 | 0 |
| 31 Mar 17 | 238 | 31 | 79 | 0 |
| 31 Dec 16 | 237 | 28 | 76 | 0 |
| 30 Sep 16 | 231 | 22 | 75 | 0 |
| 30 Jun 16 | 231 | 28 | 73 | 0 |
| 31 Mar 16 | 230 | 25 | 72 | 0 |
| 31 Dec 15 | 223 | 29 | 71 | 0 |
| 30 Sep 15 | 224 | 30 | 71 | 0 |
| 30 Jun 15 | 215 | 23 | 70 | 0 |
| 31 Mar 15 | 210 | 20 | 69 | 0 |
| 31 Dec 14 | 202 | 16 | 69 | 0 |
| 30 Sep 14 | 196 | 14 | 68 | 0 |
| 30 Jun 14 | 193 | 15 | 66 | 0 |
| 31 Mar 14 | 194 | 17 | 66 | 0 |
| 31 Dec 13 | 191 | 16 | 64 | 0 |
| 30 Sep 13 | 189 | 15 | 64 | 0 |
| 30 Jun 13 | 187 | 13 | 63 | 0 |
Quality Earnings: YSPSAH has high quality earnings.
Growing Profit Margin: YSPSAH's current net profit margins (10.5%) are higher than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YSPSAH's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: YSPSAH's earnings growth over the past year (8.3%) exceeds its 5-year average (8.1% per year).
Earnings vs Industry: YSPSAH earnings growth over the past year (8.3%) exceeded the Pharmaceuticals industry -4.8%.
Return on Equity
High ROE: YSPSAH's Return on Equity (9.4%) is considered low.